linical research is undergoing its most significant transformation in decades. Digital health technologies (DHTs), decentralized clinical trials (DCTs), and increasingly complex data ecosystems promise broader access and faster evidence generation. But innovation has outpaced governance.
Regulators have already signaled the direction. The International Council for Harmonization’s Good Clinical Practice guideline, ICH E6(R3), and its companion ICH E8(R1), make Quality by Design (QbD) a foundational expectation for modern trials. The US Food and Drug Administration (FDA) reinforces this through its guidance documents on decentralized clinical trials (DCTs), digital health technologies (DHTs), and electronic systems, electronic records, and electronic signatures in clinical investigations. Separately, the European Medicines Agency (EMA) strengthens these expectations through its Reflection Paper on decentralized elements and its guideline on computerized systems and electronic data.
The regulatory message is clear. The operational reality is not. Despite these clear signals, QbD is still inconsistently applied across the industry. Many organizations continue to rely on reactive quality checks, fragmented processes, and study-specific technology deployments that inadvertently increase site burden on investigators and compromise data integrity.
The question is no longer whether QbD is required. It is whether the industry is structurally prepared to operationalize it at scale.
Quality by Design and Its Role in Modern Trials: What QbD Really Means in Clinical Research
Originating in manufacturing and formalized by Joseph M. Juran’s Trilogy, QbD in clinical research means proactively identifying critical-to-quality (CtQ) factors, mapping risk, and embedding controls and mitigations before the first participant is enrolled. It requires understanding which data and processes truly matter for decision-making—and designing the trial accordingly.
ICH E8(R1) explicitly embeds these principles into clinical research, defining quality as “the absence of errors that matter to decision-making.” ICH E6(R3) further operationalizes this by requiring sponsors to identify critical data and processes, assess risks, and implement proportionate controls.
In decentralized environments, this becomes especially critical, because added options may introduce unintended or unknown risks.
For example, traditional trials followed a relatively unified accountability chain:
EHR → Investigator Review → EDC (Electronic Data Capture)
This model ensured clinical assessment before data submission, traceable source verification, clear accountability, and aligned oversight.
However, decentralized models often introduce a second chain:
Device/App → Vendor → Sponsor
If not deliberately integrated through QbD, this creates parallel data ecosystems with inconsistent timestamps, missing metadata, unverifiable source data, delayed safety signal visibility, and blurred accountability.
The issue is not decentralization itself. It is the absence of standardized architectural integration. Without QbD-driven data flow design, decentralization becomes fragmentation.
Where the Lack of QbD Breaks Down Today
Three systemic challenges persist due to the limited adoption of QbD:
1. Static Quality Management Systems (QMS)
Many organizations rely on rigid standard operating procedures (SOPs) that inhibit flexibility. QbD requires dynamic, risk-based decision-making, not checklists.
2. Study-Specific Technology Deployments
FDA’s DCT Guidance (2023) and DHT Guidance (2023) warn that sponsor-controlled systems can create investigator burden when they fall outside standard-of-care (SoC) workflows.
3. Fragmented Data Flows
EMA’s Reflection Paper on Decentralized Elements (2022) and Guideline on Computerized Systems (2023) highlight risks when data originate outside investigator oversight or bypass institutional systems.
A 2023 systematic review of digital health data quality found that fragmentation across multiple systems leads to higher rates of missing data, inconsistency, and poor timeliness, compromising clinical decision-making and research outcomes—all challenges addressable through systematic QbD approaches.
One sponsor applied QbD to Trial Master Files (TMF) by treating them as a critical “end product” with predefined critical-to-quality attributes and zero-defect design controls, achieving over 50% improvement in completeness and timeliness rates. This demonstrates how QbD addresses fragmented data flows in DCTs by proactively designing documentation processes to prevent compliance gaps from multisystem data integration
Why DCTs Expose the Weaknesses
Decentralized trials amplify every existing quality challenge:
- Data come from more sources
- Investigators oversee fewer activities directly
- Participants generate data outside clinical settings
- Technology vendors play a larger operational role
Without QbD, decentralization becomes fragmentation.
The Real-World Impact on Investigators, Participants, and Data Integrity: How Poor QbD Design Burdens Investigators
Investigator Capacity Shrinks
Study-specific technology is one of the biggest barriers to DCT scalability. When sponsors deploy systems that fall outside an investigator’s standard-of-care environment:
- Investigators cannot train or supervise staff under their own governance
- Credentialing becomes protocol-specific
- Workflows become fragmented
- Institutions struggle to absorb operational complexity
This shrinks the investigator pool willing to participate in complex digital trials, directly limiting participant access and scalability—the opposite of what DCTs aim to achieve.
Safety Oversight Becomes Diluted
FDA’s DHT Guidance emphasizes that investigators must have timely access to data used for safety monitoring. When DHTs transmit data directly to sponsors or vendors without structured integration into investigator review, the safety oversight chain weakens.
A 2024 study on commercial wearable devices for early adverse event detection found that real-time remote monitoring enabled earlier identification of physiological deteriorations (e.g., COVID-19 onset by 4.1 days pre-symptom), but fragmented access to integrated investigator oversight delayed clinician responses and increased intervention needs. Remote monitoring only improves safety when oversight architecture is intentionally designed.
Data Integrity Is Put at Risk
Fragmented digital ecosystems without QbD-aligned integration increase the likelihood of:
- Data reconciliation errors
- Missing metadata
- Unverifiable source data
- Incomplete audit trails
Regulators have not lowered expectations for traceability or accountability simply because trials are digital. If anything, scrutiny has increased. In fact, EMA’s computerized systems guideline explicitly warns against these risks. The risks are not abstract but result in regulatory delay, rework, reputational harm, and in extreme cases, compromised decision-making. This pressure is heightened as complex trial designs expand to support personalized treatments and increase study participation.
Why Scalability of a Modernized Clinical Trial Depends on Standards
The industry often responds to these challenges with additional SOPs, vendor oversight procedures, or monitoring adjustments. These are necessary but insufficient. DCT complexity is not a procedural problem. It is an architectural one.
Scaling decentralized trials requires structural standardization. It’s not the only way to scale DCTs, but it is the only practical way.
A QbD-based standard must:
- Define investigator responsibilities
- Map protocol activities to real clinical workflows
- Categorize schedule of activities and subactivities (data generation, recording, transfer, assessment, verification)
- Align digital tools with SoC processes
- Standardize data flow mapping
- Embed ALCOA++ and FAIR principles
The IEEE Clinical Trial Technology Modernization Network (CTTMN), a not-for-profit organization, is developing such a framework, aiming to produce a standard by 2027. However, adoption—not publication—will determine impact.
What’s Next
Five Structural Shifts:
1. Adopt QbD as the Default, Not the Exception
This requires elevating QbD from a study-level methodology to an enterprise-wide governance architecture that shapes how trials are conceived, approved, and operationalized.
Organizations must shift from reactive quality checks to proactive design. This means:
- Identifying CtQ factors early
- Designing risk-based controls
- Embedding quality into protocol development
- Using cross-functional QbD workshops
2. Align Technology With Standard-of-Care Workflows
Digital tools must be designed to integrate into existing clinical governance structures, rather than forcing investigators and institutions to operate in parallel digital ecosystems.
Sponsors should prioritize systems that:
- Integrate with electronic health records (EHRs)
- Support investigator oversight
- Minimize study-specific training
- Maintain a unified safety and data chain
3. Standardize Data Flow Mapping Across the Industry
Data flow architecture should become a standardized, transparent design artifact (not an internal afterthought), forming the backbone of accountability in digital trials.
Every organization should maintain a structured, end-to-end data flow map that includes:
- Data sources
- Transfer mechanisms
- Risks and mitigations
- Ownership
- Audit trails
This is already an expectation under ICH E6(R3) and EMA’s computerized systems guideline.
4. Participate in Standards Development
Sustainable decentralization will require pre-competitive alignment on governance models, because no single sponsor can independently solve the problem of systemic architectural fragmentation.
Regulators have set the direction. The industry must now operationalize it.
Sponsors, CROs, investigators, technology vendors, and patient groups should actively engage in:
- IEEE CTTMN QbD framework development on a pre-competitive basis
- Cross-industry working groups
- Public consultations on regulatory guidance
5. Build QbD Into Digital Transformation Strategies
Digital transformation strategies must treat governance design as a core infrastructure investment, not as a downstream compliance checkpoint.
Digital innovation without QbD is not modernization, it is risk.
Organizations should embed QbD into:
- Vendor selection
- Protocol design
- Data architecture
- Decentralized operations
- Monitoring strategies
Conclusion
Quality by Design is not a regulatory slogan. It is the governance framework that determines whether decentralized research can scale safely and credibly—the very foundation regulators expect, investigators need, and participants deserve.
The industry has embraced digital innovation. It must now modernize its quality architecture with equal urgency. To truly enable decentralized optionality, sponsor processes for study design must incorporate QbD principles, ensuring that optional elements are explicitly defined so investigators can operationalize them within their remit. Without closing this governance gap, decentralized trials will not scale; they will stagnate under inspection pressure, operational fatigue, and investigator attrition.
The path forward is clear: build quality in, align with standard of care, integrate data flows, and adopt industry-wide standards. If we succeed, we unlock what decentralization promised from the beginning: scalable, ethical, participant-centered, regulator-ready clinical research.
The choice is architectural.